- Helomics
is collaborating with the University of Pittsburgh School of Medicine to
study the use of artificial intelligence to improve clinical decision
making for ovarian cancer patients. More than 22,000 women are diagnosed
with ovarian cancer in the U.S. each year.
- Entered
an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to
develop products to diagnose and assess the risk for thyroid cancer as
well as provide appropriate therapeutic recommendations. The treatment
market for thyroid cancer is expected to reach $2.1 billion by 2025.
- Skyline
Medical has received its first order for four STREAMWAY machines to be
sold to local hospitals in India. The Indian healthcare industry is
estimated at more than $100 billion, with the nation’s medical device
industry valued at more than $6 billion.
- Helomics
signed a collaborative research agreement with Pittsburgh-based molecular
imaging company, ChemImage, to expand personalized medicine to prostate
cancer diagnosis and treatment.
- TumorGenesis
and partner 48Hour Discovery received the Alberta Innovates grant for
development of novel cancer treatments.
Predictive Oncology Inc. (NASDAQ: POAI) is a data and
artificial intelligence-driven discovery services company that provides
predictive models of tumor drug response to improve patient outcome. Predictive
Oncology harnesses the power of artificial intelligence, collaborating with the
pharmaceutical, diagnostic and biotech industries to develop highly
customizable assessment methods for patients, which can lead to much more
effective treatments.
Subsidiaries
Predictive Oncology leverages the synergies of its three
wholly owned subsidiaries to bring precision medicine to the diagnosis of
cancer.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer therapies for
patients and drive the development of new targeted therapies in collaborations
with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical
testing that assists oncologists in individualizing patient treatment decisions,
by providing an evidence-based roadmap for therapy.
In addition to its proprietary precision oncology platform,
Helomics offers boutique CRO services that leverage its TruTumor™
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary platform
(D-CHIP) to provide a tailored solution to its clients’ specific needs.
TumorGenesis is developing a new, rapid approach
to growing tumors in the laboratory, which essentially “fools” cancer cells
bind to specific biomarkers. Once the biomarkers are identified, they can be
used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and
help categorize an individual patient’s heterogeneous tumor samples to enable development
of patient specific treatment options.
Skyline Medical’s patented, FDA-cleared STREAMWAY
System is the first true, direct-to-drain fluid disposal system designed
specifically for medical applications such as radiology, endoscopy, urology and
cystoscopy procedures. The STREAMWAY system is changing the way healthcare
facilities collect and dispose of potentially infectious waste fluid by
connecting directly to a facility’s plumbing system to automate the collection,
measurement and disposal of waste fluids.
The STREAMWAY minimizes human intervention for better safety
and improves compliance with Occupational Safety and Health Administration
(OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates
canisters, carts and evacuated bottles, which reduces overhead costs and
minimizes environmental impact by helping to eliminate the approximately 50
million potentially disease-infected canisters that go into landfills annually
in the United Sates.
Skyline has achieved sales in five of the seven continents
through both direct sales and distributor partners.
Leadership Team
Dr. Carl Schwartz was appointed to Skyline Medical’s board
of directors in March 2015 and became interim president and CEO in May 2016. He
has owned and managed dental groups in Michigan and currently owns two dental
practices there. Dr. Schwartz became CEO of Plastics Research Corporation in
1988, leading the company to become the largest manufacturer of structural foam
molding products in the U.S. with more than $60 million in revenues and 300
employees by the time he retired in 2001. He holds a bachelor’s degree and DDS
degree from the University of Detroit.
CFO Bob Myers has over 30 years of experience in multiple
industries focusing on medical device service and manufacturing. He has spent
much of his career as a CFO and controller. Myers holds an MBA in Finance from
Adelphi University and a BBA in public accounting from Hofstra University.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
